Shots:
- The CHMP has recommended marketing authorization for Gedeon Richter’s Tuyory, a biosimilar version of RoActemra (Tocilizumab)
- Tuyory (tocilizumab) inhibits IL-6 signaling and is indicated for rheumatoid arthritis, juvenile idiopathic arthritis (including polyarthritis), giant cell arteritis, cytokine release syndrome, and COVID-19. It is available in both IV and SC forms, with dosing and presentations matching the reference product
- Tuyory was co-developed by Gedeon Richter and Mochida Pharmaceutical
Ref: Gedeon Richter | Image: Gedeon Richter | Press Release
Related News:- Gedeon Richter Receives the CHMP Positive Opinion for Fylrevy for Hormone Replacement Therapy (HRT)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
